This study is testing a new combination of two drugs, zanzalintinib and etoposide, for people with germ cell tumors (GCTs) that have come back or are hard to treat. You might be able to join if you have a metastatic GCT that has progressed after initial chemotherapy and at least one other treatment. Researchers want to see how safe this drug combination is and how well it prevents the cancer from growing for 12 months. The study is currently unclear about its recruitment status, but it plans to enroll around 38 participants.

Study design

This is an open-label, single-arm Phase I/II study, meaning all participants will receive the study drugs and everyone will know which drugs are being given. It will initially enroll 9 patients to test different doses of zanzalintinib.

What's involved

You would take zanzalintinib by mouth daily and etoposide by mouth for 21 days of each 28-day cycle. This treatment continues until your cancer progresses or side effects become too severe.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long you live without your cancer progressing for 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.